Reduced basal and phencyclidine-induced expression of heat shock protein-70 in rat prefrontal cortex by the atypical antipsychotic abaperidone

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 1, 2003, Pages 31-36

  García Osta, Ana ^a   Frechilla, Diana ^a   Del Río, Joaquín ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Abaperidone; Antipsychotic; Clozapine; hsp70; Prefrontal cortex

Indexed keywords

ABAPERIDONE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; HEAT SHOCK PROTEIN 70; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACTIVITY; DRUG EFFECT; MALE; NONHUMAN; PREFRONTAL CORTEX; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; SCHIZOPHRENIA; SYMPTOM;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHROMONES; HALLUCINOGENS; HSP70 HEAT-SHOCK PROTEINS; ISOXAZOLES; MALE; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, WISTAR;

EID: 0037305819     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00311-1     Document Type: Article

References (28)

1. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101.
2. Ashe P.C., Berry M.D., Boulton A.A. Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 25:2001;691-707.
3. Bolós J., Anglada L., Gubert S., Planas J.M., Agut J., Príncep M., De la Fuente A., Sacristán A., Ortiz J.A. 7-[3-(1-Piperidinyl)propoxy](chromenones as potential atypical antipsychotics: 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3- (hydroxymethyl)chromen-4-one (abaperidone. FI-8602). J. Med. Chem. 41:1998;5402-5409.
4. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 812:1998;65-75.
5. Duncan G.E., Zom S., Lieberman J.A. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypothesis of schizophrenia. Mol. Psychiatry. 4:1999;418-428.
6. Goldman-Rakic P.S., Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 23:1997;437-458.
7. Horváth Z.C., Czopf J., Buzsáki G. MK-801-induced neuronal damage in rats. Brain Res. 753:1997;181-195.
8. Ilyin V.I., Whittemore E.R., Guastella J., Weber E., Woodward R.M. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol. Pharmacol. 50:1996;1541-1550.
9. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225.
10. Kim J.J., Lee S.J., Toh K.Y., Lee C.H., Lee C., Paik I.H. Identification of antibodies to heat shock proteins 90 KDa and 70 KDa in patients with schizophrenia. Schizophr. Res. 52:2001;127-135.
11. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology. 124:1996;2-34.
12. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288:1999;774-781.
13. Lewis D.A., Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron. 28:2000;325-334.
14. Moore H., West A.R., Grace A.A. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol. Psychiatry. 46:1999;40-55.
15. Nakahara T., Kuroki T., Hondo H., Tsutsumi T., Fukuda K., Yao H., Uchimura H. Effects of atypical antipsychotic drugs vs. haloperidol on expression of heat shock protein in the discrete brain regions of phencyclidine-treated rats. Mol. Brain Res. 73:1999;193-197.
16. Nakki R., Nickolenko J., Chang J., Sagar S.M., Sharp F.R. Haloperidol prevents ketamine- and phencyclidine-induced HSP70 protein expression but not microglial activation. Exp. Neurol. 137:1996;234-241.
17. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362.
18. 2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizolcipine. J. Pharmacol. Exp. Ther. 287:1998;839-846.
19. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271:1994;1058-1066.
20. Schwarz M.J., Riedel M., Gruber R., Ackenheil M., Muller N. Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am. J. Psychiatry. 156:1999;1103-1104.
21. Sharp F.R., Butman M., Wang S., Koistinaho J., Graham S.H., Sagar S.M., Noble L., Berger P., Longo F.M. Haloperidol prevents induction of the HSP70 heat shock gene in neurons injured by phencyclidine (PCP), MK801 and ketamine. J. Neurosci. Res. 33:1992;605-616.
22. Sharp F.R., Massa S.M., Swanson R.A. Heat-shock protein protection. Trends Neurosci. 22:1999;97-99.
23. Smith D.F., Whitesell L., Katsanis E. Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol. Rev. 50:1998;493-513.
24. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effect of antipsychotic drugs. Brain Res. Rev. 31:2000;320-329.
25. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42:2002;165-179.
26. Volonte M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG80, a novel antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69:1997;182-190.
27. Voruganti L., Cortese L., Oyewumi L., Cernovsky Z., Zirul S., Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res. 43:2000;135-145.
28. Weinberger D.R., Berman K.F. Prefrontal function in schizophrenia: confounds and controversies. Philos. Trans. R. Soc. Lond., B Biol. Sci. 351:1996;1495-1503.